from a news article written by Rick Ruggles, Omaha World-Herald
OMAHA, Neb. (July 1, 2013)—University of Nebraska Medical Center researcher Howard Gendelman, M.D., will soon start a human trial on a promising new drug treatment for Parkinson’s disease.
Dr. Gendelman, chairman of UNMC’s Department of Pharmacology and Experimental Neuroscience, believes he found a way to halt the degenerative disease’s progression. Current treatments for Parkinson’s largely treat symptoms and are only effective for a short time.
Dr. Gendelman will use a two-step approach to implement his innovative treatment. The first step is to stop the disease’s progression, which will be tested in the upcoming trial.
If it works, Dr. Gendelman can move into the second part of his research: Use a vaccine he’s building to sweep out the faulty protein that causes Parkinson’s.
“We hope to cure Parkinson’s disease,” Dr. Gendelman told the Omaha World-Herald. “I know it’s a lofty goal.”
Read the entire article at the Omaha World-Herald website, Omaha.com.